Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Interventions to reduce the time to diagnosis of brain tumours. Brain tumours are recognised as one of the most difficult cancers to diagnose because presenting symptoms, such as headache, cognitive symptoms, and seizures, may be more commonly attributable to other, more benign conditions. Interventions to reduce the time to diagnosis of brain tumours include national awareness initiatives, expedited pathways, and protocols to diagnose brain tumours, based on a person's presenting symptoms (...) 2014.We planned to include studies evaluating any active intervention that may influence the diagnostic pathway, e.g. clinical guidelines, direct access imaging, public health campaigns, educational initiatives, and other interventions that might lead to early identification of primary brain tumours. We planned to include randomised and non-randomised comparative studies. Included studies would include people of any age, with a presentation that might suggest a brain tumour.Two review authors
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with MET-dysregulated advanced NSCLC. Patients were (...) assigned to cohorts on the basis of previous lines of therapy and MET status (MET exon 14 skipping mutation or MET amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the cohort assignments.A total of 364 patients
increases in risk of solid cancers (n=20 805, excluding non-melanoma skin cancers; hazard ratio 0.98, 95% confidence interval 0.96 to 1.01) or hematopoietic cancers overall (n=1807; 1.00, 0.91 to 1.10) compared with non-users. Additionally, ever users did not have an increased risk of most specific cancers (cutaneous squamous cell carcinoma, bladder cancer, melanoma, estrogen receptor positive breast cancer, progesterone receptor positive breast cancer, hormone receptor positive breast cancer, brain (...) cancer, colorectal cancer, kidney cancer, lung cancer, and most of the major subclasses and histological subtypes of hematopoietic cancer) or cancer related death (n=4860; 0.96, 0.91 to 1.02). Basal cell carcinoma risk was slightly increased for ever users (n=22 560; 1.05, 1.02 to 1.08). Cumulative dose was positively associated with risk of estrogen receptor negative breast cancer, progesterone receptor negative breast cancer, hormone receptor negative breast cancer, and ovarian cancer. An increased
, a multidisciplinary group of experts, representing Interventional Radiology, Urology, and Interventional Oncology, was convened to review the current literature on the use of ablation for the management of RCC. Literature Review A comprehensive literature search was conducted in June 2019 in MEDLINE via PubMed using a combination of the following search terms: “renal cell carcinoma,” “renal tumors,” “RCC,” “metastatic renal cancer,” “oligometastatic,” “biopsy,” “thermal ablation,” "radiofrequency ablation (...) , 0.45–2.33). Ablation versus Active Surveillance Ablation has also been compared to active surveillance using the SEER registry data. Larcher et al ( x 23 Larcher, A., Trudeau, V., Sun, M. et al. Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. BJU Int . 2016 ; 118 : 541–546 | | | 23 ) included 1860 patients with cT1a kidney cancer treated with either local tumor ablation or observation between 2000
Avapritinib (Ayvakyt) for the treatment of gastrointestinal stromal tumours (GIST) Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST) - Repository of AIHTA GmbH English | Browse - - - Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST) Grössmann, N. (2020): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Oncology Fact Sheet Nr. 16. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert
Trastuzumab for treating HER2-positive breast and gastric cancers 1 Driving better decision-making in healthcare Trastuzumab for treating HER2-positive breast and gastric cancers Technology Guidance from the MOH Drug Advisory Committee Published on 1 September 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? Trastuzumab biosimilar (Ogivri) 440 mg powder for IV injection for treating: ? HER2-positive early or metastatic breast cancer, or ? HER2 (...) -positive metastatic gastric cancer in line with its registered indications; ? The removal of trastuzumab reference biologic (Herceptin) 440 mg powder for IV injection from the Medication Assistance Fund (MAF) for all indications; and ? Not to list the new subcutaneous formulation of Herceptin (600 mg solution for injection) on the Standard Drug List (SDL) or MAF in view of unfavourable cost effectiveness compared with Ogivri at the price proposed by the manufacturer. Patients receiving Ogivri must have
, an estimated 13,940 women will die of the disease. A woman's risk of getting ovarian cancer during her lifetime is approximately 1 in 78 and her lifetime chance of dying of ovarian cancer is about 1 in 108. Approximately 85%-90% of all ovarian cancers are epithelial in origin, and approximately 70% of all epithelial ovarian cancers are high-grade serous (HGS) adenocarcinoma. Despite initial therapy, usually consisting of surgical cytoreduction and platinum-taxane combination therapy, the majority of women (...) peritoneal cancer (EOC). METHODS Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug Administration approvals, and consensus when evidence was lacking. RESULTS The systematic review identified 17 eligible trials. RECOMMENDATIONS The guideline pertains to patients who are PARPi naïve. All patients with newly diagnosed, stage III-IV EOC whose disease
team of doctors having a discussion Fellows & Early Career Resources designed for early career gastroenterologists. Search August 25, 2020 Expert guidance on screening for colorectal and pancreatic cancer in BRCA1 and BRCA2 carriers Due to modest risk estimates and limited data, screening is only recommended when BRCA1/2 carriers also have a family history of colorectal cancer or pancreatic ductal adenocarcinoma. Share on facebook Share on twitter Share on linkedin Share on email Drs. Sonia S (...) . Kupfer, Samir Gupta, Jeffrey Weitzel and Jewel Samadder provide their expert opinion on colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) risk and screening strategies in BRCA1 and BRCA2 carriers. Read this AGA Clinical Practice Update in the August issue of Gastroenterology: Risk estimates and recommendations After reviewing all available evidence, our experts identify that for CRC there is a 1.5-fold increased risk for BRCA1 carriers, and no increased risk in BRCA2 carriers
develop into colorectal cancer (CRC). Deep learning systems allow for real-time computer-aided detection (CADe) of polyps with high accuracy. We performed a multicenter, randomized trial to assess the safety and efficacy of a CADe system in detection of colorectal neoplasias during real-time colonoscopy. Methods: We analyzed data from 685 subjects (61.32 ± 10.2 years old; 337 men) undergoing screening colonoscopies for CRC, post-polypectomy surveillance, or workup due to positive results from a fecal (...) minutes was required. Lesions were collected and histopathology findings were used as the reference standard. The primary outcome was adenoma detection rate (ADR, the percentage of patients with at least 1 histologically proven adenoma or carcinoma). Secondary outcomes were adenomas detected per colonoscopy, non-neoplastic resection rate, and withdrawal time. Results: The ADR was significantly higher in the CADe group (54.8%) than in the control group (40.4%) (relative risk [RR], 1.30; 95% confidence
, Brest, France. PMID: 32654348 DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Background: The Registro Informatizado de Pacientes con Enfermedad TromboEmbólica (RIETE) score and the Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) risk scores aim to identify patients with acute unprovoked venous thromboembolism (VTE) at high risk of occult cancer, but their predictive performance is unclear. Methods: The scores were (...) ), eight (5.0%) were diagnosed with cancer compared with 29 of 764 (3.8%) low-risk patients (HR, 1.2; 95% CI, 0.55-2.7). Conclusions: The predictive discriminatory performance of both scores is poor. When used dichotomously, the RIETE score is able to discriminate between low- and high-risk patients. Because this is largely driven by advanced age, these results do not support the use of these scores in daily clinical practice. Keywords: cancer; diagnosis; early detection of cancer; neoplasms; venous
Display options Format Abstract Patients with metastatic renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and have shown limited responsiveness to inhibition of the VEGF pathway. We conducted a prespecified analysis of the randomised, phase 3 IMmotion151 trial in previously untreated patients with advanced or metastatic RCC to assess the effectiveness of atezolizumab + bevacizumab versus sunitinib in a subgroup of patients with sarcomatoid features. Patients whose tumour had (...) atezolizumab + bevacizumab achieved an objective response (49% vs 14%), including complete responses (10% vs 3%), and reported greater symptom improvements versus sunitinib. Safety was consistent with the known profiles of each drug and with that reported in the overall safety-evaluable population of IMmotion151. This analysis supports enhanced activity of atezolizumab + bevacizumab in patients with sRCC. PATIENT SUMMARY: In this report, we looked at patients with a specific type of kidney cancer (tumours
Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. Surveillance with annual mammography and breast magnetic resonance imaging (MRI) is recommended for female survivors of childhood cancer treated with chest radiation, yet benefits, harms, and costs are uncertain.To compare the benefits, harms, and cost-effectiveness of breast cancer screening strategies in childhood cancer (...) survivors.Collaborative simulation modeling using 2 Cancer Intervention and Surveillance Modeling Network breast cancer models.Childhood Cancer Survivor Study and published data.Women aged 20 years with a history of chest radiotherapy.Lifetime.Payer.Annual MRI with or without mammography, starting at age 25, 30, or 35 years.Breast cancer deaths averted, false-positive screening results, benign biopsy results, and incremental cost-effectiveness ratios (ICERs).Lifetime breast cancer mortality risk without screening
Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model. Lung cancer screening with chest computed tomography (CT) reduces lung cancer death. Centers for Medicare & Medicaid Services (CMS) eligibility criteria for lung cancer screening with CT require detailed smoking information and miss many incident lung cancers. An automated deep-learning approach based on chest radiograph images may (...) identify more smokers at high risk for lung cancer who could benefit from screening with CT.To develop and validate a convolutional neural network (CXR-LC) that predicts long-term incident lung cancer using data commonly available in the electronic medical record (EMR) (chest radiograph, age, sex, and whether currently smoking).Risk prediction study.U.S. lung cancer screening trials.The CXR-LC model was developed in the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial (n = 41 856
Cancer Tips, Advice, and Support – Prostate Centre Canada – Canadian Cancer Society – Diagnostic Code: 185 (malignantneoplasm of prostate) Abbreviations CCO - Cancer Care Ontario DRE - digital rectal exam ERSPC - European Randomized Study of Screening for Prostate Cancer LUTS - lower urinary tract symptoms PSA - prostate specific antigen This guideline is based on scientific evidence current as of November 2017 (refer to Methodology ). The guideline was developed by the BC Cancer Primary Care (...) the age of 60 when they are diagnosed and most men will survive their prostate cancer. It is estimated that 1 in 29 men who are diagnosed with prostate cancer would be expected to die of the disease. The following risk factors are associated with an increased risk of prostate cancer and should be considered when assessing men who present with symptoms or with questions about testing: Men of African descent. Family history of prostate cancer (paternal side; first-degree relatives (i.e., father
[ Kerkhofs T.M. Verhoeven R.H. Van der Zwan J.M. et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013; 49 : 2579-2586 , Kebebew E. Reiff E. Duh Q.Y. et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?. World J Surg. 2006; 30 : 872-878 ]. Phaeochromocytomas are catecholamine-producing neuroendocrine tumours arising from chromaffin cells of the adrenal medulla or extra (...) Network for the Study of Adrenal Tumors. European Journal of Endocrinology. 2016; 175 : G1-G34 ]. Additional measurements of plasma methoxytyramine, a biomarker now increasingly available, provide useful information to assess the likelihood of malignancy [ Eisenhofer G. Lenders J.W. Siegert G. et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012; 48